All In Biotech

Drug Trial Radar · NCT06272812

A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.

A Phase 2b, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine, MTBVAC, Against TB Disease in Adolescents and Adults Aged 14-45 Years, Living in a TB Endemic Region.

Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 5,531 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

5,531

Actual

Start

Feb 19, 2025

Primary completion

Dec 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
International AIDS Vaccine InitiativeResearch network
Sponsor type
Research network
Collaborators
Biofabri, SLU; Universidad de Zaragoza
First posted
Feb 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 14 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in adolescents and adults aged 14-45 years, living in a TB endemic region.

Conditions

  • Tuberculosis (TB)

Interventions

  • MTBVACBiological

    Vaccine Dose: MTBVAC 5x10\^5 Formulation (approximately, per standard dose): 3 - 17x10\^5 CFU Sucrose Sodium glutamate Presentation: Lyophilized pellet in vials (10 doses) Volume: 0.1 mL/dose Intradermal

  • PlaceboBiological

    0.9% saline Volume: 0.1 mL/dose Intradermal

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the protective efficacy of MTBVAC against bacteriologically confirmed PTB, not associated with HIV infection, diagnosed by more than one diagnostic test with sputum obtained before initiation of TB treatment, in baseline IGRA-positives.Time frame: 36 Months

Locations

16 sites in 3 countries. Site status is shown where the registry gives one.

  • Victoria Biomedical Research Institute

    Kisumu, Kenya

  • Kenya Medical Research Institute

    Nairobi, Kenya

  • JOSHA Research

    Bloemfontein, South Africa

  • South African Tuberculosis Vaccine Initiative

    Cape Town, South Africa

  • TASK Applied Science Pty Ltd. TASK Delft

    Cape Town, South Africa

  • UCTLI CLII - Centre for Lung Infection and Immunity

    Cape Town, South Africa

  • University of Cape Town Lung Institute PtyLtd. Centre for Tuberculosis Research Innovation

    Cape Town, South Africa

  • Wellcome Centre for Infectious Diseases Research in Africa

    Cape Town, South Africa

  • Synergy Biomedical Research Institute

    East London, South Africa

  • TASK Eden Pty Ltd.

    George, South Africa

  • Perinatal HIV Research Unit

    Johannesburg, South Africa

  • Be Part Research Pty Ltd.

    Paarl, South Africa

  • The Aurum Institute Rustenburg Clinical Research Centre

    Rustenburg, South Africa

  • Desmond Tutu Health Foundation, Masiphumelele Research Office

    Sunnydale, South Africa

  • The Aurum Institute Tembisa Clinical Research Centre

    Tembisa, South Africa

  • Ifakara Health Institute

    Dar es Salaam, Tanzania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.